Home Investigators Publications News Events Leducq

Robert E. Gerszten, MD

Contact

rgerszten @ partners.org

Biography

Dr. Robert Gerszten is Director of Translational Research in the Cardiology Division at the Massachusetts General Hospital, with a joint appointment in the MGH Center for Immunology and Inflammatory Diseases. Dr. Gerszten is an Associate Professor at Harvard Medical School. He is also a Senior Associate at the Broad Institute of Harvard and MIT. Dr. Gerszten received his medical education at Johns Hopkins University and completed his cardiovascular clinical and research training at the University of California, San Francisco and the Massachusetts General Hospital.

Research Summary

Dr. Gerszten's research efforts have focused on understanding the molecular basis of injury responses in cardiovascular disease. His laboratory has incorporated emerging proteomics and metabolomics technologies to help identify novel signals derived from leukocytes, endothelial cells, or from the myocardium. In ongoing translational studies, his group applies these same methodologies directly to samples from well-phenotyped human cohorts to identify candidate biomarkers, returning again to the bench to define functional roles. The research incorporates basic molecular and cell biology, chemistry and mass spectrometry, bioinformatics, all with a foundation in clinical medicine. The overall goal is to identify new metabolites and proteins that mark cardiovascular disease activity, shed insight into disease progression, and provide targets for therapeutic intervention.

Metabolomic assessment of exercise

Publications

1. Sabatine MS, Liu E, Morrow DA, Heller E, McCarroll R, Wiegand R, Berriz GF, Roth FP, Gerszten RE. Metabolomic identification of novel biomarkers of myocardial ischemia. Circulation 2005; 112: 3868-3875.
2. Gerszten RE, Garcia-Zepeda EA, Lim YC, Yoshida M, Ding HA, Gimbrone MA, Jr., Luster AD, Luscinskas FW, Rosenzweig A. MCP-1 and IL-8 trigger firm adhesion of monocytes to vascular endothelium under flow conditions. Nature 1999; 398: 718-723.
3. Liu E, Sinha S, Williams C, Cyrille M, Heller E, Snapper SB, Georgopoulos K, St-Arnaud R, Force T, Dedhar S, Gerszten RE. Targeted deletion of integrin-linked kinase reveals a role in T-cell chemotaxis and survival. Mol Cell Biol 2005; 25: 11145-11155.
4. Heller EA, Liu E, Tager AM, Sinha S, Roberts JD, Koehn SL, Libby P, Aikawa ER, Chen JQ, Huang P, Freeman MW, Moore KJ, Luster AD, Gerszten RE. Inhibition of atherogenesis in BLT1-deficient mice reveals a role for LTB4 and BLT1 in smooth muscle cell recruitment. Circulation 2005; 112: 578-586.
5. Heller EA, Liu E, Tager AM, Yuan Q, Lin AY, Ahluwalia N, Jones K, Koehn SL, Lok VM, Aikawa E, Moore KJ, Luster AD, Gerszten RE. Chemokine CXCL10 promotes atherogenesis by modulating the local balance of effector and regulatory T cells. Circulation 2006; 113: 2301-2312.

Last updated 10/19/2007.